Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rapid decrease in unintegrated human immunodeficiency virus DNA after the initiation of nucleoside therapy

R M Donovan1, C E Bush, S M Smereck

  • 1Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan 48202.

The Journal of Infectious Diseases
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postantibiotic effect and postantibiotic sub-MIC effect of LTX-109 and mupirocin on Staphylococcus aureus blood isolates.

Letters in applied microbiology·2017
Same author

NMO-IgG positive relapsing longitudinally extensive transverse myelitis (LETM) in a seropositive HIV patient.

Clinical neurology and neurosurgery·2013
Same author

Fast soft x-ray images of magnetohydrodynamic phenomena in NSTX.

The Review of scientific instruments·2008
Same author

Diagnostics for the biased electrode experiment on NSTX.

The Review of scientific instruments·2008
Same author

Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance.

International journal of STD & AIDS·2008
Same author

Detection of Streptococcus pneumoniae colonisation in respiratory tract secretions of military personnel.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2007
Same journal

Retraction of: Tracking Plasmodium knowlesi Through Fecal DNA for Monitoring Zoonotic Transmission in Wild Macaques Across Southeast and South Asia.

The Journal of infectious diseases·2026
Same journal

Can malaria induce loss of vaccine immunity.

The Journal of infectious diseases·2026
Same journal

NET-inducing ability of Cutibacterium acnes clinical isolates is associated with pathogenicity in acne vulgaris.

The Journal of infectious diseases·2026
Same journal

Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.

The Journal of infectious diseases·2026
Same journal

Monitoring HLA-A2-restricted T cell responses and BCLA-specific serostatus during human latent Toxoplasma gondii infection suggests the implication of CD8+ T cells in parasite containment.

The Journal of infectious diseases·2026
Same journal

Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).

The Journal of infectious diseases·2026
See all related articles

Measuring unintegrated human immunodeficiency virus (HIV) DNA (uDNA) in patients shows promise as a new marker for assessing antiretroviral therapy effectiveness. HIV uDNA levels rapidly declined during treatment, indicating its potential as a therapeutic efficacy marker.

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Effective monitoring of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection is crucial.
  • Current markers for therapeutic efficacy may not fully capture treatment response.
  • Novel biomarkers are needed to assess the effectiveness of antiretroviral drugs.

Purpose of the Study:

  • To evaluate unintegrated HIV DNA (uDNA) as a potential biomarker for determining the therapeutic efficacy of nucleoside antiretroviral therapy.
  • To assess the kinetics of HIV uDNA levels during the initiation of therapy.

Main Methods:

  • Quantitative polymerase chain reaction (PCR) assay was used to measure HIV DNA levels.
  • Peripheral blood mononuclear cells (PBMC) were collected from 20 HIV-infected patients initiating nucleoside therapy.

Related Experiment Videos

  • Sequential measurements of HIV uDNA were performed at baseline and at weeks 1, 4, and 8 of therapy.

    • Main Results:

    • Before therapy, 19 out of 20 patients had detectable HIV uDNA, averaging 42% of total HIV DNA.
    • Following 8 weeks of nucleoside therapy, the average percentage of HIV uDNA decreased significantly to 3% (P < .001).
    • HIV uDNA levels decreased in all patients within the first week, becoming undetectable in 14 patients by week 8.

    Conclusions:

    • Measurement of HIV uDNA demonstrates significant potential as a reliable marker for antiretroviral drug efficacy.
    • HIV uDNA exhibits key characteristics of a good therapeutic marker, including high detectability, rapid response to therapy, and a plausible biological mechanism.
    • This marker could aid in optimizing HIV treatment strategies and monitoring patient response to antiretroviral drugs.